Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506

J. Fukunaga, T. Yamaai, Eiki Yamachika, Y. Ishiwari, H. Tsujigiwa, K. Sawaki, Y. J. Lee, T. Ueno, S. Kirino, Nobuyoshi Mizukawa, S. Takagi, N. Nagai, T. Sugahara

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Immunosuppressant drugs are currently required by transplant recipients for the remainder of their lives, despite the many adverse effects associated with these therapies. Acute osteoporosis is one such effect, and a reproducible osteoporosis model has been established through the administration of the immunosuppressant drug FK506 in rats. The cause of this osteoporosis has been shown to be abnormal osteoclast proliferation, altering the process of bone remodeling. However, the reasons why FK506 induces osteoclast proliferation and whether this process is mediated by cytokine changes or an increase in bone resorption factors have been unclear. An investigation was therefore conducted focusing on the recent discoveries of osteoclast differentiation factor (ODF) and osteoclastogenesis inhibitory factor (OCIF). These factors led to elucidation of the osteoclast differentiation-maturation mechanism. An osteoporosis model was produced in rats utilizing intramuscular FK506 injection (1 mg/kg) for 28 consecutive days. Trabecular bone resorption was observed inferior to enchondral ossification in the FK506 group, and tartrate resistant acid phosphatase (TRAP) staining revealed a clear increase in osteoclasts at the site of enchondral ossification, relative to the control group. Real-time PCR and in situ hybridization (ISH) demonstrated minimal differences in OCIF expression between control and the treatment groups. However, Real-time PCR revealed clearly increased ODF expression in the treatment group. ODF expression was also shown to be increased in the treatment group using ISH. This was histologically consistent with a region of osteoclast proliferation inferior to enchondral ossification. The results of this study support the hypothesis that FK506-mediated osteoporosis occurs by action of the drug on osteoclasts, promoting expression of ODF messenger ribonucleic acid (mRNA) and thus prompting osteoclast differentiation and maturation.

Original languageEnglish
Pages (from-to)425-431
Number of pages7
JournalBone
Volume34
Issue number3
DOIs
Publication statusPublished - Mar 2004

Fingerprint

RANK Ligand
Osteoprotegerin
Tacrolimus
Osteoclasts
Immunosuppressive Agents
Osteoporosis
Osteogenesis
In Situ Hybridization
Real-Time Polymerase Chain Reaction
Pharmaceutical Preparations
Control Groups
Bone Remodeling
Intramuscular Injections
Therapeutics
Bone Resorption
RNA
Staining and Labeling
Cytokines

Keywords

  • FK506
  • Immunosuppressant
  • OCIF
  • ODF
  • Osteoblast
  • Osteoporosis

ASJC Scopus subject areas

  • Physiology
  • Hematology

Cite this

Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. / Fukunaga, J.; Yamaai, T.; Yamachika, Eiki; Ishiwari, Y.; Tsujigiwa, H.; Sawaki, K.; Lee, Y. J.; Ueno, T.; Kirino, S.; Mizukawa, Nobuyoshi; Takagi, S.; Nagai, N.; Sugahara, T.

In: Bone, Vol. 34, No. 3, 03.2004, p. 425-431.

Research output: Contribution to journalArticle

Fukunaga, J, Yamaai, T, Yamachika, E, Ishiwari, Y, Tsujigiwa, H, Sawaki, K, Lee, YJ, Ueno, T, Kirino, S, Mizukawa, N, Takagi, S, Nagai, N & Sugahara, T 2004, 'Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506', Bone, vol. 34, no. 3, pp. 425-431. https://doi.org/10.1016/j.bone.2003.05.003
Fukunaga, J. ; Yamaai, T. ; Yamachika, Eiki ; Ishiwari, Y. ; Tsujigiwa, H. ; Sawaki, K. ; Lee, Y. J. ; Ueno, T. ; Kirino, S. ; Mizukawa, Nobuyoshi ; Takagi, S. ; Nagai, N. ; Sugahara, T. / Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506. In: Bone. 2004 ; Vol. 34, No. 3. pp. 425-431.
@article{d059f38a661f452698028e901b6c4a21,
title = "Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506",
abstract = "Immunosuppressant drugs are currently required by transplant recipients for the remainder of their lives, despite the many adverse effects associated with these therapies. Acute osteoporosis is one such effect, and a reproducible osteoporosis model has been established through the administration of the immunosuppressant drug FK506 in rats. The cause of this osteoporosis has been shown to be abnormal osteoclast proliferation, altering the process of bone remodeling. However, the reasons why FK506 induces osteoclast proliferation and whether this process is mediated by cytokine changes or an increase in bone resorption factors have been unclear. An investigation was therefore conducted focusing on the recent discoveries of osteoclast differentiation factor (ODF) and osteoclastogenesis inhibitory factor (OCIF). These factors led to elucidation of the osteoclast differentiation-maturation mechanism. An osteoporosis model was produced in rats utilizing intramuscular FK506 injection (1 mg/kg) for 28 consecutive days. Trabecular bone resorption was observed inferior to enchondral ossification in the FK506 group, and tartrate resistant acid phosphatase (TRAP) staining revealed a clear increase in osteoclasts at the site of enchondral ossification, relative to the control group. Real-time PCR and in situ hybridization (ISH) demonstrated minimal differences in OCIF expression between control and the treatment groups. However, Real-time PCR revealed clearly increased ODF expression in the treatment group. ODF expression was also shown to be increased in the treatment group using ISH. This was histologically consistent with a region of osteoclast proliferation inferior to enchondral ossification. The results of this study support the hypothesis that FK506-mediated osteoporosis occurs by action of the drug on osteoclasts, promoting expression of ODF messenger ribonucleic acid (mRNA) and thus prompting osteoclast differentiation and maturation.",
keywords = "FK506, Immunosuppressant, OCIF, ODF, Osteoblast, Osteoporosis",
author = "J. Fukunaga and T. Yamaai and Eiki Yamachika and Y. Ishiwari and H. Tsujigiwa and K. Sawaki and Lee, {Y. J.} and T. Ueno and S. Kirino and Nobuyoshi Mizukawa and S. Takagi and N. Nagai and T. Sugahara",
year = "2004",
month = "3",
doi = "10.1016/j.bone.2003.05.003",
language = "English",
volume = "34",
pages = "425--431",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Expression of osteoclast differentiation factor and osteoclastogenesis inhibitory factor in rat osteoporosis induced by immunosuppressant FK506

AU - Fukunaga, J.

AU - Yamaai, T.

AU - Yamachika, Eiki

AU - Ishiwari, Y.

AU - Tsujigiwa, H.

AU - Sawaki, K.

AU - Lee, Y. J.

AU - Ueno, T.

AU - Kirino, S.

AU - Mizukawa, Nobuyoshi

AU - Takagi, S.

AU - Nagai, N.

AU - Sugahara, T.

PY - 2004/3

Y1 - 2004/3

N2 - Immunosuppressant drugs are currently required by transplant recipients for the remainder of their lives, despite the many adverse effects associated with these therapies. Acute osteoporosis is one such effect, and a reproducible osteoporosis model has been established through the administration of the immunosuppressant drug FK506 in rats. The cause of this osteoporosis has been shown to be abnormal osteoclast proliferation, altering the process of bone remodeling. However, the reasons why FK506 induces osteoclast proliferation and whether this process is mediated by cytokine changes or an increase in bone resorption factors have been unclear. An investigation was therefore conducted focusing on the recent discoveries of osteoclast differentiation factor (ODF) and osteoclastogenesis inhibitory factor (OCIF). These factors led to elucidation of the osteoclast differentiation-maturation mechanism. An osteoporosis model was produced in rats utilizing intramuscular FK506 injection (1 mg/kg) for 28 consecutive days. Trabecular bone resorption was observed inferior to enchondral ossification in the FK506 group, and tartrate resistant acid phosphatase (TRAP) staining revealed a clear increase in osteoclasts at the site of enchondral ossification, relative to the control group. Real-time PCR and in situ hybridization (ISH) demonstrated minimal differences in OCIF expression between control and the treatment groups. However, Real-time PCR revealed clearly increased ODF expression in the treatment group. ODF expression was also shown to be increased in the treatment group using ISH. This was histologically consistent with a region of osteoclast proliferation inferior to enchondral ossification. The results of this study support the hypothesis that FK506-mediated osteoporosis occurs by action of the drug on osteoclasts, promoting expression of ODF messenger ribonucleic acid (mRNA) and thus prompting osteoclast differentiation and maturation.

AB - Immunosuppressant drugs are currently required by transplant recipients for the remainder of their lives, despite the many adverse effects associated with these therapies. Acute osteoporosis is one such effect, and a reproducible osteoporosis model has been established through the administration of the immunosuppressant drug FK506 in rats. The cause of this osteoporosis has been shown to be abnormal osteoclast proliferation, altering the process of bone remodeling. However, the reasons why FK506 induces osteoclast proliferation and whether this process is mediated by cytokine changes or an increase in bone resorption factors have been unclear. An investigation was therefore conducted focusing on the recent discoveries of osteoclast differentiation factor (ODF) and osteoclastogenesis inhibitory factor (OCIF). These factors led to elucidation of the osteoclast differentiation-maturation mechanism. An osteoporosis model was produced in rats utilizing intramuscular FK506 injection (1 mg/kg) for 28 consecutive days. Trabecular bone resorption was observed inferior to enchondral ossification in the FK506 group, and tartrate resistant acid phosphatase (TRAP) staining revealed a clear increase in osteoclasts at the site of enchondral ossification, relative to the control group. Real-time PCR and in situ hybridization (ISH) demonstrated minimal differences in OCIF expression between control and the treatment groups. However, Real-time PCR revealed clearly increased ODF expression in the treatment group. ODF expression was also shown to be increased in the treatment group using ISH. This was histologically consistent with a region of osteoclast proliferation inferior to enchondral ossification. The results of this study support the hypothesis that FK506-mediated osteoporosis occurs by action of the drug on osteoclasts, promoting expression of ODF messenger ribonucleic acid (mRNA) and thus prompting osteoclast differentiation and maturation.

KW - FK506

KW - Immunosuppressant

KW - OCIF

KW - ODF

KW - Osteoblast

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=12144287995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144287995&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2003.05.003

DO - 10.1016/j.bone.2003.05.003

M3 - Article

C2 - 15003790

AN - SCOPUS:12144287995

VL - 34

SP - 425

EP - 431

JO - Bone

JF - Bone

SN - 8756-3282

IS - 3

ER -